MRI of tumor angiogenesis
- PMID: 17623889
- DOI: 10.1002/jmri.20991
MRI of tumor angiogenesis
Abstract
Angiogenesis has long been established as a key element in the pathophysiology of tumor growth and metastasis. Increasingly, new molecularly targeted antiangiogenic drugs are being developed in the fight against cancer. These drugs bring with them a need for an accurate means of diagnosing tumor angiogenesis and monitoring response to treatment. Imaging techniques can offer this in a noninvasive way, while also providing functional information about the tumor. Among the many clinical imaging techniques available, MRI alone can provide relatively good spatial resolution and specificity, without ionizing radiation and with limited side effects. Arterial spin labeling (ASL) and blood oxygenation level-dependent (BOLD) imaging techniques can be employed to confer indirect measures of angiogenesis, such as blood flow and blood volume, without the need for external contrast agents. Dynamic contrast-enhanced (DCE)-MRI is rapidly emerging as a standard method for directly measuring angiogenesis during angiogenesis-inhibitor drug trials. As macromolecular MR contrast agents become available, they will inevitably be utilized in the assessment of tumor perfusion and vessel permeability. Meanwhile, technological advances have made imaging at a molecular level a possibility. They have brought the potential to directly target MR contrast agents to markers of angiogenesis, such as the alpha(v)beta(3) integrin. Before this is used clinically, however, substantial gains in sensitivity brought about by improved coils, pulse sequences, and contrast agents will be needed. Herein we discuss the techniques currently available for MRI of angiogenesis, along with their respective advantages and disadvantages, and what the future holds for this evolving field of imaging.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Macromolecular MRI contrast agents for imaging tumor angiogenesis.Eur J Radiol. 2006 Dec;60(3):353-66. doi: 10.1016/j.ejrad.2006.06.025. Epub 2006 Aug 23. Eur J Radiol. 2006. PMID: 16930905 Review.
-
Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s. doi: 10.1158/1078-0432.CCR-06-1921. Clin Cancer Res. 2007. PMID: 17255308 Review.
-
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.Cancer Res. 2003 Sep 15;63(18):5838-43. Cancer Res. 2003. PMID: 14522907
-
Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment.J Natl Cancer Inst Monogr. 2011;2011(43):103-7. doi: 10.1093/jncimonographs/lgr031. J Natl Cancer Inst Monogr. 2011. PMID: 22043053
-
Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment.Abdom Imaging. 2006 Mar-Apr;31(2):188-93. doi: 10.1007/s00261-005-0386-5. Abdom Imaging. 2006. PMID: 16447089 Review.
Cited by
-
The Correlation between Morpho-Dynamic Contrast-Enhanced Mammography (CEM) Features and Prognostic Factors in Breast Cancer: A Single-Center Retrospective Analysis.Cancers (Basel). 2024 Feb 22;16(5):870. doi: 10.3390/cancers16050870. Cancers (Basel). 2024. PMID: 38473232 Free PMC article.
-
Biomarkers in Cancer Detection, Diagnosis, and Prognosis.Sensors (Basel). 2023 Dec 20;24(1):37. doi: 10.3390/s24010037. Sensors (Basel). 2023. PMID: 38202898 Free PMC article. Review.
-
Quantitative Ultrasound for Evaluation of Tumour Response to Ultrasound-Microbubbles and Hyperthermia.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231200993. doi: 10.1177/15330338231200993. Technol Cancer Res Treat. 2023. PMID: 37750232 Free PMC article.
-
DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.Front Oncol. 2022 Dec 12;12:925186. doi: 10.3389/fonc.2022.925186. eCollection 2022. Front Oncol. 2022. PMID: 36578948 Free PMC article.
-
Feasibility of Arterial Spin Labeling Magnetic Resonance Imaging for Musculoskeletal Tumors with Optimized Post-Labeling Delay.Diagnostics (Basel). 2022 Oct 10;12(10):2450. doi: 10.3390/diagnostics12102450. Diagnostics (Basel). 2022. PMID: 36292139 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials